Table 1.

Available therapies targeting IL-17 and IL-23 in IMIDs.

Mechanism of action	Therapy	Approved indications*	PsO	PsA	axSpA	HS	IBD	Uveitis
Anti-IL-17A	Ixekizumab	Plaque psoriasis, psoriatic arthritis, axial spondylarthritis
	Secukinumab	Plaque psoriasis, psoriatic arthritis, axial spondylarthritis, juvenile idiopathic arthritis
Anti-IL-17RA	Brodalumab	Plaque psoriasis
Anti IL-17A and IL-17F	Bimekizumab	Plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. Phase 3 clinical development completed for hidradenitis suppurativa, EMA approval pending
Anti-IL12/23	Ustekinumab	Plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis
Anti-IL23p19	Guselkumab	Plaque psoriasis, psoriatic arthritis. In phase 3 clinical development for Crohn’s disease and ulcerative colitis
	Risankizumab	Plaque psoriasis, psoriatic arthritis, Crohn’s disease. In phase 3 clinical development for ulcerative colitis
	Tildrakizumab	Plaque psoriasis. In phase 3 clinical development for psoriatic arthritis

axSpA, axial spondyloarthritis; HS, hidradenitis suppurativa; IBD, inflammatory bowel disease; IL, interleukin; PsA, psoriasis arthritis; PsO, psoriasis.

*The table only includes therapies that have been approved by the European Medicines Agency (EMA) or that have published phase 3 clinical development.

Green: approved or shown efficacy in phase 3 clinical trials. Red: Lack of efficacy. Yellow: Insufficient or unclear evidence.